Indocyanine green-mediated photothrombosis for choroidal neovascularization in angioid streaks.
OBJECTIVE
To investigate the effect of indocyanine green-mediated photothrombosis on choroidal neovascularization secondary to angioid streaks.


METHODS
Six eyes of 5 patients with an average age of 70 years were diagnosed to have subfoveal choroidal neovascularization secondary to angioid streaks. Therapy was indicated if choroidal neovascularization was considered to be active, according to evidence of fluorescein leakage on angiograms, as well as presence of intra- or subretinal fluid on optical coherence tomography. Patients received photothrombosis at baseline with retreatment as necessary at 3, 6 and 9 months follow-up. Fluorescein leakage was assessed at 3, 6 and 9 months, along with foveal thickness measured by optical coherence tomography. Indocyanine green angiography was performed initially and whenever retreatment was considered. Retreatment was performed whenever there was evidence of increased leakage on fluorescein angiograms at follow-up visits.


RESULTS
The mean follow-up was 13.3 months. All eyes had at least 12 months follow-up. Two eyes underwent retreatment. Three eyes had visual acuity improvement and three eyes had stabilization. All patients showed less fluorescein leakage on final angiograms and reduced foveal thickness upon optical coherence tomography measurement.


CONCLUSIONS
Photothrombosis is a feasible procedure for choroidal neovascularization secondary to angioid streaks. Lesion analysis showed anatomical improvement in most cases in this series. Further studies are warranted to evaluate long-term results of this treatment.
Malerbi
Fernando Korn
FK
Departamento de Oftalmologia, Universidade Federal de São Paulo, São Paulo, SP, Brasil. femalerbi@terra.com.br
Huang
Sheau Jiun
SJ
Aggio
Fabio Bom
FB
Carvalho
Edenilson
E
Bonomo
Pedro Paulo
PP
Farah
Michel Eid
ME
D000328:Adult; D000368:Aged; D000793:Angioid Streaks / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004396:Coloring Agents / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green / Q000627:therapeutic use*; D017075:Laser Coagulation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
D004396:Coloring Agents; D007208:Indocyanine Green